SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment.
COVID-19
SARS-CoV-2
azithromycin
culture
hydroxychloroquine
qRT-PCR
viral persistence
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
12 05 2021
12 05 2021
Historique:
received:
11
03
2021
revised:
07
05
2021
accepted:
08
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
2
7
2021
Statut:
epublish
Résumé
SARS-CoV-2 nasopharyngeal shedding contributes to the spread of the COVID-19 epidemic. Among 3271 COVID-19 patients treated at the Hospital University Institute Méditerranée Infection, Marseille, France from 3 March to 27 April 2020, tested at least twice by qRT-PCR, the median SARS-CoV-2 nasopharyngeal shedding duration was 6 days (range 2-54 days). Compared with short shedders (qRT-PCR positivity < 10 days), 34 (1.04%) persistent shedders (qRT-PCR positivity ≥ 17 days; mean ± SD: 23.3 ± 3.8 days) were significantly older, with associated comorbidities, exhibiting lymphopenia, eosinopenia, increased D-dimer and increased troponin (
Identifiants
pubmed: 34065871
pii: v13050890
doi: 10.3390/v13050890
pmc: PMC8150993
pii:
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : Méditerranée infection 10-IAHU-03
Commentaires et corrections
Type : CommentIn
Références
Travel Med Infect Dis. 2020 Jul - Aug;36:101632
pubmed: 32205269
Open Forum Infect Dis. 2021 Apr 28;8(11):ofab217
pubmed: 34796242
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Pediatr Pulmonol. 2020 Oct;55(10):2504-2505
pubmed: 32735761
J Infect Dis. 2021 May 20;223(9):1522-1527
pubmed: 33556961
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e293-e295
pubmed: 33235142
J Clin Immunol. 2021 Feb;41(2):356-361
pubmed: 33219491
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
Int J Infect Dis. 2020 Sep;98:252-260
pubmed: 32619760
Ann Palliat Med. 2021 Jun;10(6):7003-7007
pubmed: 33183020
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
Travel Med Infect Dis. 2021 Mar-Apr;40:101980
pubmed: 33535105
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
J Infect Dis. 2021 Jan 4;223(1):23-27
pubmed: 33089317
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
J Infect Dis. 2020 Sep 1;222(7):1103-1107
pubmed: 32702095
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Clin Infect Dis. 2021 Aug 2;73(3):e815-e821
pubmed: 33507235
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
J Infect Chemother. 2021 Feb;27(2):387-389
pubmed: 33328135
Scand J Trauma Resusc Emerg Med. 2020 Jul 13;28(1):66
pubmed: 32660623
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Microorganisms. 2021 Feb 02;9(2):
pubmed: 33540596
Clin Infect Dis. 2021 Dec 6;73(11):e4020-e4024
pubmed: 33103195
medRxiv. 2020 Dec 29;:
pubmed: 33398302
Infect Dis Health. 2020 Aug;25(3):210-215
pubmed: 32473952